MedTrace Logo

Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

NCT00351871 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2009-02-04

No results posted yet for this study

Summary

The objective of this study is to better understand the influence of insulin resistance upon treatment response in hepatitis C virus treated with PEG Intron and Rebetol.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

PEG-Intron Plus REBETOL

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Louisiana State University Health Sciences Center in New Orleans

    lead OTHER

Principal Investigators

  • William M. Cassidy, M.D. · Louisiana State University Health Sciences Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2007-11-30
Completion
2007-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351871 on ClinicalTrials.gov